세계의 암 모노클로널 항체 시장 규모는 2022년에 739억 달러로 평가되며, 2023년 875억 달러에서 2031년에는 3,379억 2,000만 달러로 확대하며, 예측 기간 중(2024-2031년) 18.40%의 CAGR로 성장할 전망입니다.
모노클로널 항체(mAb) 치료는 화학요법, 방사선 치료, 수술과 같은 기존 치료법을 보완하는 암 치료의 중요한 요소라는 인식이 확산되고 있습니다. 지난 20년 동안 mAb는 고형암과 혈액암 모두에서 매우 효과적인 치료법으로 자리 잡으며 암 발병률 증가와 강력한 신약 승인 파이프라인을 촉진했습니다. 현재 및 향후 승인될 예정인 mAb 치료제는 기존 화학요법에 비해 부작용이 상대적으로 적다는 치료적 이점이 있으며, 전 세계 수백만 명의 환자들에게 혜택을 줄 수 있는 잠재력을 가지고 있습니다. 저렴한 가격의 바이오시밀러 모노클로널 항체가 의료진에 의해 더 많이 수용되면서 예측 기간 중 시장 성장이 더욱 가속화될 것으로 예상됩니다. 그러나 COVID-19는 암 검진 수검률에 부정적인 영향을 미쳤으며, 2020년 4월 유방암 검진 수검률은 이전과 비교하여 87%나 급감했습니다. 이러한 감소는 치료의 상당한 지연을 초래하여 필요한 항암제에 대한 적시 접근, 질병 재발 및 치료 지연에 대한 우려를 불러일으키고 있습니다. 암은 여전히 억제되지 않는 세포 증식을 특징으로 하는 주요 만성질환으로, 암 발병률 증가는 앞으로도 mAb 치료제에 대한 수요를 주도하며 시장 확대를 견인할 것으로 보입니다. 전반적으로 암 치료제 시장 중 mAb 분야는 혁신적인 암 치료제에 대한 니즈와 팬데믹 이후 의료 접근성의 발전으로 인해 성장할 수 있는 여건이 조성되고 있습니다.
Global Cancer Monoclonal Antibodies Market size was valued at USD 73.9 billion in 2022 and is poised to grow from USD 87.5 billion in 2023 to USD 337.92 billion by 2031, growing at a CAGR of 18.40% during the forecast period (2024-2031).
Monoclonal antibody (mAb) therapies are increasingly recognized as crucial components in the cancer treatment landscape, complementing traditional modalities such as chemotherapy, radiation, and surgery. Over the past two decades, mAbs have established themselves as highly effective treatments for both solid tumors and hematologic malignancies, spurred by rising cancer incidence rates and a robust pipeline of new drug approvals. Current and forthcoming mAb therapies hold the potential to benefit millions globally, offering a therapeutic advantage due to their relatively lower side effects compared to conventional chemotherapy. The growing acceptance of affordable biosimilar monoclonal antibodies by healthcare providers is expected to further enhance market growth in the forecast period. However, the COVID-19 pandemic has negatively impacted cancer screening rates, with a dramatic 87% drop observed in breast cancer screenings in April 2020 compared to previous years. This decline resulted in significant treatment delays, raising concerns about timely access to necessary cancer medications, disease recurrence, and the postponement of therapies. As cancer remains a major chronic disease characterized by unchecked cell proliferation, the escalating incidence of cancer cases will likely continue to drive demand for mAb therapies and bolster market expansion in the coming years. Overall, the mAb segment of the oncology market stands poised for growth, fueled by both the need for innovative cancer treatments and the evolution of healthcare access in a post-pandemic landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cancer Monoclonal Antibodies Market Segmental Analysis
Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Driver of the Global Cancer Monoclonal Antibodies Market
The Global Cancer Monoclonal Antibodies market is significantly driven by the alarming rise in cancer prevalence worldwide, which underscores the urgent need for innovative and effective treatment options. Monoclonal antibodies are favored over traditional therapies due to their ability to selectively target malignant cells, thereby improving treatment efficacy and minimizing adverse effects. As patient demand for advanced therapeutic solutions escalates, the market is further bolstered by increased investments in research and development aimed at discovering novel monoclonal antibody-based therapies. Furthermore, heightened awareness surrounding cancer leads to earlier detection and treatment initiation, propelling growth and development within this vital sector of oncology.
Restraints in the Global Cancer Monoclonal Antibodies Market
A significant market restraint for the global cancer monoclonal antibodies market is the prohibitively high cost associated with monoclonal antibody therapies. The advanced manufacturing processes and extensive research and development required for these therapies contribute to their steep pricing. This financial burden limits patient access, particularly among low-income communities and in countries with strained healthcare budgets. As a result, the expensive nature of these treatments may render them unaffordable for many, leading to increased out-of-pocket expenses and further hindering market growth and accessibility. This economic barrier could ultimately restrict the adoption of these potentially life-saving therapies across diverse populations.
Market Trends of the Global Cancer Monoclonal Antibodies Market
The Global Cancer Monoclonal Antibodies market is witnessing a significant trend towards the integration of combination therapies, reflecting an evolving landscape in oncology treatment. By leveraging monoclonal antibodies in conjunction with immunotherapies, targeted therapies, and chemotherapy, healthcare providers aim to combat cancer on multiple fronts, enhancing treatment efficacy while minimizing resistance. The synergistic effects observed, particularly with immune checkpoint inhibitors paired with monoclonal antibodies, underscore the potential for improved patient outcomes through deeper immune responses against tumors. This trend not only highlights the complexity of cancer but also emphasizes the shift towards personalized medicine, offering tailored and potent treatment options for diverse patient profiles.